Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR-NK cell therapy for relapsed or resistant B-cell acute lymphoblastic leukemia
IRCT20200413047063N5Phase 2Completed
- Sponsor
- Omid Cell and Tissue Processing
- Start
- Jun 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Anti-CD19 CAR-NK cells in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Omid Cell and Tissue Processing. Primary endpoints: Incidence of dose-limiting toxicity, Maximum tolerated dose and 3 more. Started Jun 2024; status: completed.
02
Drugs
Anti-CD19 CAR-NK cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on IRCT20200413047063N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200413047063N5.